The Novel Conjugates Summit is the only industry-led forum dedicated entirely to novel payload and targeting format innovation in antibody-drug conjugate (ADC) development. It brings together the discovery, bioconjugation and R&D scientists working on the next generation of conjugates, with no traditional ADC content on the agenda.
Now in its 6th year, the summit unites 80+ leaders from big pharma, ADC biotech and novel conjugate biotech to share new data, benchmark approaches and work through the translational challenges of taking differentiated conjugates toward the clinic.
Novel conjugates are bioconjugates where either the payload or the delivery format is out of the ordinary. Instead of a classical cytotoxic payload such as Topo1 inhibitors or MMAE on a monoclonal antibody, they use new mechanisms or new ways of targeting the tumor to tackle resistance, improve selectivity and widen the therapeutic window.
The program spans the most advanced areas of novel conjugate development:
- Dual-payload ADCs
- Pathway-directed (targeted-pathway) payloads
- Degrader-antibody conjugates (DACs)
- Bispecific and biparatopic ADCs
- Immune-stimulating and immune-modulating conjugates
- Antibody-oligonucleotide conjugates (AOCs) and conjugates beyond oncology
- Peptide, fragment and other non-antibody conjugates
March 29-31, 2027, Boston, MA.
The Colonnade Hotel, 120 Huntington Ave, Boston, MA 02116
Boston and Cambridge host one of the densest concentrations of pharma, biotech and academic research in the world, including many ADC and novel conjugate teams. That keeps travel easy for much of the audience while remaining accessible to international delegates.
Three days in total: One pre-conference Workshop Day followed by two Conference Days.
80+ discovery, bioconjugation and R&D leaders. The group is kept deliberately small, so there is time to meet and talk with everyone in the room.
To see the latest data on the most advanced novel payloads and formats, benchmark your approach against peers working on the same challenges, and hear what is and is not translating from preclinical promise to the clinic. In a room this size, those conversations carry on well after the event.
2026 marked a turning point for novel conjugates, moving them from emerging innovation to a strategic priority across the ADC landscape. Several factors are driving that shift:
- The first bispecific ADC, iza-bren, reached the market with China's NMPA approval in June 2026
- Big pharma is investing, with deals and acquisitions including Eli Lilly and CrossBridge Bio, Johnson & Johnson and Firefly Bio, Novartis and Myricx Bio, and Regeneron and Parabilis
- More dual-payload and alternative-payload programs are entering the clinic
- Saturation of classical ADC payloads and the rising threat of patient resistance are pushing developers to differentiate
- New data is arriving faster than any single meeting can cover
The 6th Novel Conjugates Summit is built to put that data and those decisions in front of the scientists who need them.
The summit is designed for scientists and leaders working on conjugates day to day. Attendees typically include:
- Directors, Vice Presidents and Heads of discovery, oncology and ADC research
- Bioconjugation and bioconjugate chemistry specialists
- Medicinal chemistry and chemistry leaders
- Tumor and cancer biology scientists
- Antibody and protein engineering experts
- Pharmacokinetics and DMPK specialists
- Preclinical and translational scientists
- Chief Scientific Officers and R&D leaders at emerging biotechs
The speaker faculty draws on teams from across pharma and biotech, including Astellas, AstraZeneca, Akari Therapeutics, Callio Therapeutics, CanWell Pharma, Corellia AI, DCx Bio, Hexagon Bio, Iksuda, K2B Therapeutics, Salubris Bio and VelaVigo Therapeutics.
The summit runs across three days:
- Workshop Day, with two in-depth, discussion-led workshops
- Conference Day 1 and Day 2, a single-track programme of data presentations, a Burning Questions session and structured networking
The ADC calendar includes flagship meetings such as World ADC, as well as specialist events such as ADC Linker & Conjugation and ADC Payload. The Novel Conjugates Summit is positioned differently:
- Novel only: no traditional ADC content, so every session is relevant to novel payload and format programs
- Science and data first: built around research and translational insight for discovery and early development teams
- Intimate by design: 80+ attendees, rather than a large flagship crowd, with time to connect with everyone
- Payload and format focus: complementary to events centered on linker and conjugation technology or payload chemistry
The Workshop Day takes place the day before the main conference and offers two focused, discussion-led sessions. Topics are rational design of novel conjugates, which means pairing payload mechanism, target and format, and the preclinical signposts that show a program is ready for IND. Each workshop includes small-group discussion and practical frameworks you can take back to your team.
The Workshop Day is offered alongside the two Conference Days. Please see the pricing page for package options, or email info@hansonwade.com.
Networking is central to the summit. With 80+ delegates, most attendees get to know each other by name. Opportunities include:
- Speed networking on Conference Day 1
- Extended breaks and refreshments on all three days
- A poster session on Conference Day 1
- Lunch on all three days
- A Burning Questions session where attendees pool their experience on the open questions raised during the meeting
Yes. Dual-payload ADCs are one of the most active areas in novel conjugate development, and the program addresses them directly, including payload selection, PK and ratio control, and early tolerability.
Yes. The program covers bispecific and biparatopic design, target pairing, and how dual targeting can improve selectivity and internalization across heterogeneous tumors.
Yes. Sessions cover non-traditional payloads such as pathway inhibitors, degraders and other alternative-mechanism payloads designed to overcome resistance to Topo1 and MMAE.
Yes. A dedicated part of the program looks at oligonucleotide and immune-modulating conjugates, and how conjugate platforms are being extended into autoimmune, infectious and rare disease.
The focus is discovery, preclinical and early development, with attention to translation and the first clinical data as novel conjugates progress. It is not a manufacturing or late-stage commercial meeting.
Yes, if novel conjugates are part of your pipeline or strategy. Many ADC developers are building earlier-stage novel candidates alongside their traditional programs, and the summit gives you a focused view of where the field is heading.
The summit is built for practitioners actively working in the area, and sessions assume familiarity with ADC concepts. If your team is scaling up its novel conjugate work, the peer access alone is one of the fastest ways to benchmark where you stand.
Yes. A poster session takes place on Conference Day 1. You must be registered to attend, and abstracts are submitted for review. See the Poster Session page for details, or email info@hansonwade.com.
Partnership options include presentation slots and hosted networking, designed to put your capabilities in front of discovery and R&D leaders choosing partners for novel conjugate programs. For sponsorship and exhibition enquiries, please email sponsor@hansonwade.com.
Early registration savings are available: save up to $1,000 when you register by Friday, December 11, 2026. Group rates for teams attending together: Given the small format of this summit, registering early is recommended.
Download the complimentary Event Guide from the website for the full agenda, speaker faculty, pricing and venue information. For anything else, our team is happy to help.
For registration inquiries and speaking opportunities, please contact info@hansonwade.com.
For sponsorship and exhibition inquiries, please contact sponsor@hansonwade.com.
Explore the Agenda
Preview data-led sessions on dual-payload, pathway-directed, degrader and bispecific conjugates, and two pre-conference workshops on rational design and preclinical signposts. Download the event guide for the full agenda and speaker faculty across three days.
Partner With Us